1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations
August 13, 2018 04:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that the first enrolled patient in the phase 1b study of its non-opioid, afferent nerve...